Good News! Delta Variant Is Further Mutating To Give Us “Delta Plus” Variant! We are On Target For A Predicted Catastrophic COVID-19 Surge Starting In Late July!
To those ignorant virologists and researchers that kept on insisting that the present SARS-CoV-2 variants cannot further mutate or evolve to become more potent, more transmissible or even more adapt at evading immune responses, we suggest that they crawl back to shade of their coconut shells as the SARS-CoV-2 virus is proving them all wrong and its little doubt we should even be surprised that the novel virus is gradually evolving to become more dangerous, after all it was manipulated by unscruplous scientists in laboratory to be the perfect destructive bioweapon. (We have to thank both the American and Chinese authorities for this gift to mankind especially Dr Anthony Fauci and various American billionaire technocrats and even pharma giants that all had a role in the creation of this pandemic along with the CCP and the WHO.)
In late April, Thailand Medical News once again made a prediction that a catastrophic global COVID-19 surge would start materializing sometime in August 2021 with a buildup to the end of the year. We however made adjustments based on a published modeling study and also on emerging data of the SARS-CoV-2 mutations and prevailing trends.
We are happy to announce that we are on course for that surge and new data has already emerged that most of the new variants including the various variants of concern or VOCs are already further evolving and becoming more evasive towards immune responses, antibodies and also vaccines and are become more transmissible. What is also interesting and is not being properly monitored is that the pathogenic behavior of these new variants are also slightly different and that they are attacking the various human cellular pathways in newer ways and causing more medical conditions, some which can be slowly manifesting but with dire consequences. We also have good news that numerous of these new variants are also gradually gaining dominance in circulation.
One variant of concern that is also showing not only a new evolved version but is gaining prevalence in circulation is the Delta variant that initially appeared in India. A second generation variant from the B.1.617 lineage and is officially called the B.617.2 variant, this second generation variant has spawned a new third generation variant called ‘Delta Plus’ or or the 'AY.1' variant. This third generation variant spots an additional K417N mutation which many experts claim to be associated with even further antibody evasion.
This new variant has already been identified in genome samplings in India and England.
Initial data suggests that the Delta plus variant shows signs of resistance against certain monoclonal antibody cocktail treatmen
ts. Some of these treatments were recently authorized by the Central Drugs Standard Control Organisation (CDSCO) in India.
A research scientist specialising in genomic sequencing, Dr Bani Jolly said on Twitter, "A small number of sequences of Delta (B.1.617.2) having spike mutation K417N can be found on GISAID. As of today, these sequences have been identified in genomes from 10 countries."
He told Thailand Medical News via a phone interview, "The sequences have recently been designated as lineage AY.1 (B.1.617.2.1), a sublineage of Delta, due to concerns about K417N being one of the mutations found in the Beta variant B.1.351.”
Public Health England, in its latest report on coronavirus variants, said the Delta plus variant was identified in six genomes from India as of June 7. The health agency has confirmed the presence of a total of 63 genomes of the Delta variant with the new K417N mutation.
The alarming report also has a mention of the variant in 36 cases in England. Two of the 36 were possible breakthrough infections.
Cases have also been reported USA, Canada, Switzerland, Russia, Poland, Portugal Nepal, Turkey, Malaysia and Singapore.
Dr Jolly warned, "Looking at the large (T95I) cluster, it seems like AY.1 has arisen independently a number of times and could be more prevalent than observed in countries with limited genomic surveillance.”
Experts say that the formation of Delta plus variant was the result of a mutation in the spike protein of SARS-COV-2. It is the same spike protein which enables the virus to enter and infect human cells.
Looking at the large (T95I) cluster, it seems like AY.1 has arisen independently a number of times and could be more prevalent than observed in countries with limited genomic surveillance.
Researchers said the mutation in the Delta variant was evading the monoclonal antibody treatment for COVID-19.
A scientist at Delhi-based CSIR-Institute of Genomics and Integrative Biology (IGIB), Dr Vinod Scaria told Thailand Medical News, "One important point to consider regarding K417N is evidence suggesting resistance to monoclonal antibodies Casirivimab and Imdevimab. The antibody cocktail has accidentally received an EUA from the drug controller general in India."
Leading Indian immunologist Dr Vineeta Bal said the Delta plus variant's resistance to monoclonal antibody cocktail is a key warning factor. Dr Bal is a guest faculty at Pune's Indian Institute of Science Education and Research.
She added, "How transmissible this new variant is will be a crucial factor to determine its rapid spread or otherwise."
A director of CSIR-IGIB, pulmonologist Dr Anurag Agarwal, said that it is concerning as the new variant seems to be gaining prevalence gradually.
He added, “An important point to consider regarding K417N is the evidence suggesting resistance to monoclonal antibodies Casirivimab and Imdevimab. Monoclonal antibodies, which were considered to be a viable treatment for Covid-19, has been touted to be as game changer’ in the fight against the pandemic. Monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Researchers have revealed that the use of mAbs is the foremost innovative approach that could prevent as well as treat infected patients. Several researchers are focusing on developing new cures based on specific mAbs to inhibit and/or neutralize SARS-CoV-2 in COVID-19 patients. Casirivimab and Imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, and designed to block the virus attachment and entry into human cells.”
Scientist said the blood plasma from many fully vaccinated individuals will have to be tested against this variant to determine whether it shows any significant immune escape. As the Delta variant continues to evolve and acquire new mutations, there is a lot of interest in understanding its evolution.
News would like to highlight the following key points: A) The Delta Plus Variant is just one of the many examples of third and later generation variants emerging with more concerning mutations on them. A similar situation has been found with regards to the other VOCs found in South Africa, Brazil and Kent. B) These new variants are gaining dominance in circulation and are fast appearing globally most likely due to convergent evolution. Most worrying is that some of these new variants cannot be detected by existing tests and also there is lack of adequate genomic surveillance still.C) Preliminary observational studies are also indicating that many existing drugs such as remdesivir, ivermectin, hydroxychloroquine, various existing herbal/phytochemical and TCM formulations are not working against these new third and fouth generation variants along with even antibody therapeutics and vaccines. (More studies on these are expected to be published soon.)
But again, the good news is that we are on course to see a major global catastrophic surge arise in coming weeks despite false claims on the success of controlling the pandemic by certian unscrupulous politicians around the world and health experts. The coming weeks and months will indeed be interesting times.
Keep on logging to Thailand Medical News if you intent on keeping yourself and your loved ones alive.